LACTOLOGY FOUNDATION

Betamethasone (ATC A07EA04) — Toxico-Lactological Monograph

ATC class and general pharmacology

Betamethasone under ATC code A07EA04 belongs to group A07E ("Intestinal anti-inflammatory agents"), subgroup A07EA ("Corticosteroids acting locally"), a class comprising enemas, foams, and rectal preparations used for the local treatment of distal ulcerative colitis and proctitis. This code is distinct from the systemic (H02AB01), dermatological (D07AC01), and ophthalmic (S01BA06) ATC assignments of betamethasone, which correspond to different routes of administration and pharmacokinetic profiles.atcddd.fhi+1

Betamethasone is a synthetic, 9α-fluorinated glucocorticoid (a stereoisomer of dexamethasone) with high affinity for the intracellular glucocorticoid receptor and negligible mineralocorticoid activity. Upon receptor binding, the activated complex translocates to the nucleus, where it transrepresses NF-κB– and AP-1–dependent transcription of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), inhibits phospholipase A2, and reduces the synthesis of prostaglandins and leukotrienes, producing potent anti-inflammatory and immunosuppressive effects. Its relative anti-inflammatory potency is approximately 25–30 times that of hydrocortisone, and its biological half-life (HPA-axis suppression duration) is long, in the range of 36–54 hours, classifying it among the long-acting glucocorticoids.

In the A07EA04 formulation, betamethasone is delivered as a rectal enema or retention formulation intended to act topically on the colonic mucosa, minimizing systemic exposure relative to oral or parenteral corticosteroid therapy. However, because inflamed and ulcerated colonic mucosa has increased permeability, and because the colon possesses substantial absorptive capacity, this "locally acting" classification does not equate to negligible systemic bioavailability, a point of direct toxicological and lactological relevance discussed below.

Toxicological profile

Despite its topical intent, betamethasone administered rectally is absorbed to a clinically significant degree. Pharmacokinetic evaluation of daily betamethasone enemas in patients with ulcerative colitis has documented high plasma concentrations sufficient to induce iatrogenic Cushing syndrome, with suppression of the hypothalamic-pituitary-adrenal (HPA) axis reversing only after the dosing schedule was reduced from daily to three times weekly. Older case series using high-dose retention enemas similarly reported systemic corticosteroid effects in the majority of patients receiving more than minimal doses.pubmed.ncbi.nlm.nih+1

Mechanistically, this reflects the general absorptive behavior of corticosteroid enemas in inflammatory bowel disease: an estimated 30–50% of a hydrocortisone enema dose is absorbed across the rectal/colonic mucosa, and comparable or greater absorption is expected for more potent, more lipophilic agents such as betamethasone. This distinguishes betamethasone from newer topically acting steroids such as budesonide or beclometasone dipropionate, which undergo extensive first-pass hepatic or gut-wall metabolism (up to ~90% for budesonide) and therefore produce markedly less HPA-axis suppression and fewer Cushingoid effects at equivalent local efficacy (PubMed, beclometasone enema study; PMC review of rectal corticosteroids).pubmed.ncbi.nlm.nih+2

Clinically relevant toxicities of systemically absorbed betamethasone include: adrenal suppression and adrenal crisis risk on abrupt withdrawal after prolonged use, Cushingoid features (weight gain, moon facies, striae), hyperglycemia, hypertension, osteoporosis and increased fracture risk with chronic exposure, increased susceptibility to infection due to immunosuppression, neuropsychiatric disturbances (insomnia, mood lability), and growth suppression when used long-term in pediatric patients. Because betamethasone has low plasma protein binding relative to other corticosteroids, a greater unbound (pharmacologically active) fraction is available for tissue and membrane transfer, a property with direct implications for placental and lactational transfer.

Lactation pharmacology and infant exposure

No dedicated pharmacokinetic study has quantified the excretion of rectally administered betamethasone into human milk; this specific administration route has not been directly studied in lactating women. In the absence of direct rectal-route data, the systemic pharmacokinetic profile of betamethasone must be used as the basis for risk assessment, since, as established above, the A07EA04 rectal formulation produces clinically meaningful systemic absorption comparable to other systemically administered corticosteroid regimens.e-lactancia

Authoritative lactation-safety reviews note that systemic betamethasone "has not been well studied during breastfeeding" and recommend that it is "best avoided in favor of one of the shorter-acting and better-studied alternatives" — such as prednisone or prednisolone — specifically because betamethasone's high potency and low protein binding favor greater passage into milk (LactMed, NCBI Bookshelf; PubMed summary). By comparison, milk levels of prednisone/prednisolone are well characterized and correlate with maternal dose (peak milk levels approximately 28–627 mcg/L across reported oral doses of 10–120 mg), with peak concentration occurring roughly 2 hours post-dose and no adverse effects reported in breastfed infants at typical therapeutic doses.ncbi.nlm.nih+2

A further lactation-specific concern is the effect of betamethasone on lactogenesis rather than direct infant toxicity: administration of betamethasone in the peripartum period (e.g., for fetal lung maturation) has been associated with delayed lactogenesis II and reduced milk volume during the first postpartum week; a similar mechanism (transient suppression of milk supply) has been reported after local/injected corticosteroid administration in postpartum women. No published case reports document overt adverse effects in infants breastfed during maternal rectal betamethasone therapy specifically, but this reflects an absence of dedicated study rather than confirmed safety.e-lactancia+1

Lactological safety assessment and clinical recommendations

Given the demonstrated systemic absorption of rectally administered betamethasone (A07EA04) and its unfavorable pharmacokinetic profile for lactation (high potency, low protein binding, long half-life), this agent should be classified as a corticosteroid of limited lactation safety data with potential risk during prolonged, high-dose, or frequent (daily) administration. It should not be equated with genuinely low-bioavailability topical or inhaled corticosteroid preparations, which are considered compatible with breastfeeding due to negligible systemic and milk concentrations.sps.nhs

Clinical recommendations:

• Preferred alternatives: Where clinically feasible for the same indication (distal ulcerative colitis/proctitis), rectal budesonide foam or enema should be considered as a first-line alternative to betamethasone enema, given its substantially lower systemic bioavailability due to extensive first-pass hepatic metabolism and correspondingly lower expected infant exposure.accessdata.fda
• Dose and frequency minimization: If betamethasone enema therapy is required, use the lowest effective dose for the shortest necessary duration, and favor reduced-frequency regimens (e.g., alternate-day or three-times-weekly dosing) over daily administration, which has been shown to reduce HPA-axis suppression and systemic steroid burden.pubmed.ncbi.nlm.nih
• Breastfeeding continuity: Routine interruption of breastfeeding is not required for short, low-dose courses; however, for prolonged or high-dose therapy, clinicians should weigh the maternal therapeutic benefit against theoretical infant corticosteroid exposure on an individualized basis.
• Infant monitoring: During prolonged or high-dose maternal therapy, monitor the breastfed infant for signs of adrenal suppression, unusual irritability, poor weight gain, or Cushingoid features, and consider pediatric endocrinology input if clinically indicated.
• Milk supply monitoring: Because corticosteroid exposure (particularly peripartum) can delay lactogenesis II or transiently reduce milk volume, maternal milk supply should be monitored proactively, especially if antenatal corticosteroids were also administered.
• Multidisciplinary decision-making: Management decisions should involve coordinated input from the treating gastroenterologist, a lactation consultant, and the infant's pediatrician, particularly in cases requiring maintenance or repeated courses of rectal corticosteroid therapy during lactation.